Evoke Pharma (NASDAQ:EVOK – Get Rating) is set to issue its quarterly earnings data after the market closes on Tuesday, March 21st.
Evoke Pharma Trading Down 14.8 %
NASDAQ:EVOK opened at $2.83 on Friday. The stock has a market cap of $9.45 million, a price-to-earnings ratio of -1.03 and a beta of 0.41. The company’s 50 day moving average price is $3.46 and its 200-day moving average price is $2.51. Evoke Pharma has a 52 week low of $1.37 and a 52 week high of $16.80. The company has a quick ratio of 6.94, a current ratio of 7.06 and a debt-to-equity ratio of 0.90.
Analyst Upgrades and Downgrades
Separately, StockNews.com started coverage on shares of Evoke Pharma in a research note on Wednesday. They set a “sell” rating for the company.
About Evoke Pharma
Evoke Pharma, Inc is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. It develops Gimoti, with promotility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus.
Read More
- Get a free copy of the StockNews.com research report on Evoke Pharma (EVOK)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
